Defence Therapeutics Appoints Dr. Elias Theodorou as Chief Operating Officer
Montreal, Quebec – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), a leading Canadian biopharmaceutical company specializing in the development of radiopharmaceuticals, ADC (Antibody-Drug Conjugates) products, and immune-oncology vaccines using proprietary platforms and drug delivery technologies, is thrilled to announce the appointment of Dr. Elias Theodorou as the new Chief Operating Officer (COO), effective from April 2025.
Background of Dr. Elias Theodorou
Dr. Elias Theodorou brings a wealth of experience to Defence Therapeutics. He holds a Ph.D. in Immunology from the University of Toronto, where he conducted research on the role of the immune system in cancer. Prior to joining Defence, Dr. Theodorou served as the Vice President of Research and Development at Immunovaccine Inc., where he led the development of innovative oncology therapies. He also previously held positions at the University Health Network and the Hospital for Sick Children in Toronto.
Impact on Defence Therapeutics
Dr. Theodorou’s expertise in immunology and oncology research will be a valuable asset to Defence Therapeutics as the company continues to develop innovative radiopharmaceuticals, ADC products, and immune-oncology vaccines. In his role as COO, he will oversee the day-to-day operations of the company and work closely with the executive team to drive growth and success.
Personal Impact
As a patient, this appointment signifies a step forward in the development of innovative and effective cancer treatments. Dr. Theodorou’s extensive experience in the field of oncology research and his dedication to improving patient outcomes make him an excellent addition to the Defence Therapeutics team.
Global Impact
The global impact of this appointment reaches beyond the biopharmaceutical industry. With the increasing prevalence of cancer worldwide, the development of new and effective treatments is crucial. Defence Therapeutics’ commitment to innovation in the field, coupled with the expertise of Dr. Theodorou, positions the company to make a significant impact on the global cancer landscape.
Conclusion
The appointment of Dr. Elias Theodorou as COO of Defence Therapeutics is an exciting development for the biopharmaceutical industry and for the millions of people affected by cancer worldwide. With his extensive background in immunology and oncology research, Dr. Theodorou is poised to make a significant contribution to the company’s continued growth and success. As a patient, this appointment offers hope for the development of new and effective cancer treatments, and as a global citizen, it represents a step forward in the fight against cancer.
- Defence Therapeutics Appoints Dr. Elias Theodorou as COO
- Dr. Theodorou brings extensive experience in immunology and oncology research
- Impact on Defence Therapeutics: Dedicated leader to drive growth and success
- Personal Impact: Hope for new and effective cancer treatments
- Global Impact: Significant contribution to the fight against cancer
